Kidney Week

Educational Symposium

A Practical Approach to Using SGLT2 Inhibitors for Cardiorenal Protection

October 24, 2020 | 01:00 PM - 02:00 PM

Location: Simulive

Session Description

Sodium glucose cotransporter 2 (SGLT2) is responsible for the majority of glucose reabsorption in the proximal tubule. SGLT2 inhibitors increase urinary glucose excretion and lower blood glucose. SGLT2 inhibitors also have non-glycemic effects on improvements in blood pressure, lipids, and uric acid levels.

Recent studies of SGLT2 inhibitors among patients with diabetes or heart failure have found a decreased risk of heart failure, cardiovascular mortality, and kidney disease progression. Because the trial medications were given in addition to standard-of-care treatments for diabetic kidney disease and heart failure, use of SGLT2 inhibitors will need to be integrated with these other treatments. Such integration may involve adjustment of diuretics, antihypertensives, and glucose-lowering medications.

This symposium reviews recently published outcome studies and offers plan for using these medications in clinical practice.

Support is provided by an educational grant from AstraZeneca Pharmaceuticals.

Learning Objective(s)

• Discuss the evidence from clinical trials of the cardiorenal benefits of SGLT2 inhibitors
• Describe a treatment plan for integrating SGLT2 inhibitors into the care of patients with diabetic kidney disease or heart failure

Learning Pathway(s)

• Hypertension and CVD
• Diabetes and Metabolism

Moderator

• Giuseppe Remuzzi, MD

Presentations

• Introduction
  01:00 PM - 01:10 PM
  Giuseppe Remuzzi, MD 
  
  

  Giuseppe Remuzzi, MD

  Giuseppe Remuzzi, M.D. Director, Mario Negri Institute for Pharmacological Research IRCCS and Professor of nephrology, University of Milan. His main research interests include the causes of glomerulonephritis and the mechanisms of progression of kidney diseases. He has also conducted many studies in the field of transplant rejection. In recognition of his achievements, he received many national and international awards, among them the John P. Peters Award (American Society of Nephrology 2007, San Francisco) and the “Lennox K. Black International Prize for Excellence in Medicine” (Thomas Jefferson University, Philadelphia). Prof. Remuzzi is the author of over 1500 publications in international medical journals and has written 19 books.

Introduction

October 24, 2020 | 01:00 PM - 01:10 PM

Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.

• Cardiorenal Outcomes with SGLT2 Inhibitors
  01:10 PM - 01:35 PM
  Ian H. de Boer, MD, MS
  
  Ian H. de Boer, MD, MS

Cardiorenal Outcomes with SGLT2 Inhibitors

October 24, 2020 | 01:10 PM - 01:35 PM

Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.

• Integrating SGLT2 Inhibitors into the Management of Diabetes and Heart Failure
  01:35 PM - 02:00 PM
  Amy K. Mottl, MD, FASN, MPH 
  
  

  Amy K. Mottl, MD, FASN, MPH

Integrating SGLT2 Inhibitors into the Management of Diabetes and Heart Failure

October 24, 2020 | 01:35 PM - 02:00 PM

Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.